At the time of writing, Akari Therapeutics Plc ADR [AKTX] stock is trading at $0.82, down -16.34%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AKTX shares have lost -19.62% over the last week, with a monthly amount glided 8.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akari Therapeutics Plc ADR [NASDAQ: AKTX] stock has seen the most recent analyst activity on July 18, 2025, when Maxim Group initiated its Buy rating and assigned the stock a price target of $5. Previously, B. Riley FBR upgraded its rating to Buy on January 04, 2019, and elevated its price target to $3. On February 08, 2018, B. Riley FBR Inc. initiated with a Neutral rating and assigned a price target of $3 on the stock. William Blair upgraded its rating to a Outperform. Chardan Capital Markets upgraded its rating to a Neutral but $6 remained the price target by the analyst firm on May 31, 2017. Chardan Capital Markets reiterated a Sell rating for this stock on April 17, 2017, and downed its price target to $5. In a note dated July 11, 2016, Chardan Capital Markets initiated an Sell rating and provided a target price of $5 on this stock.
For the past year, the stock price of Akari Therapeutics Plc ADR fluctuated between $0.57 and $3.15. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. Akari Therapeutics Plc ADR [NASDAQ: AKTX] shares were valued at $0.82 at the most recent close of the market. An investor can expect a potential return of 3558.54% based on the average AKTX price forecast.
Analyzing the AKTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at -571.16%, Pretax Profit Margin comes in at -471.84%, and Net Profit Margin reading is -471.84%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.78 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Akari Therapeutics Plc ADR [NASDAQ:AKTX] has a current ratio of 0.19. As well, the Quick Ratio is 0.19, while the Cash Ratio is 0.16.
Transactions by insiders
Recent insider trading involved Gaslightwala Abizer, CEO, that happened on Aug 21 ’25 when 10000.0 shares were purchased. CEO, Gaslightwala Abizer completed a deal on Aug 22 ’25 to buy 8000.0 shares. Meanwhile, CEO Gaslightwala Abizer bought 3000.0 shares on Aug 25 ’25.
